bms-986104

BMS-986104 is an investigational small molecule drug developed by Bristol Myers Squibb. It acts as a selective modulator of the sphingosine 1-phosphate receptor 1 (S1P1), functioning as a partial agonist with ligand-biased signaling properties. The compound was designed to provide immunomodulatory effects similar to fingolimod but with improved cardiovascular and pulmonary safety profiles. BMS‑986104 is a prodrug that is converted in vivo to its active phosphate metabolite (BMS‑986104-P). Preclinical studies demonstrated efficacy in T-cell transfer colitis models and suggested reduced risk of bradycardia compared to first-generation S1P modulators. Clinical development has included Phase 1 trials evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects and for rheumatoid arthritis[3][5][10].

Other names

(1R,3S)-1-amino-3-((6R)-6-hexyl-5,6,7,8-tetrahydro-2-naphthalenyl)cyclopentyl]methanolUNII KJ9D084FO4CAS 1622180-31-7CAS1622180-31-7CAS-1622180-31-7